Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Events

B Riley Securities 2022 Oncology Conference
 January 28, 2022
 2:00pm - 2:30pm EST

Cardiff Oncology CEO, Mark Erlander, PhD, will participate in a fireside chat at the B Riley Securities 2022 Oncology Conference on Friday, January 28th from 2:00 - 2:30 pm ET. To access the webcast please use the link provided.